Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Gage S BlackXiaomeng HuangYi QiaoSzabolcs TarapcsákKerry A RogersShrilekha MisraJohn C ByrdGabor T MarthDeborah M StephensJennifer A WoyachPublished in: Blood (2022)